Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A  Single-center Experience

Conclusion Ibrutinib is a highly effective and tolerable drug for B-cell malignancies in the general community. In contrast to the previously reported rate of 5% to 7%, we observed a higher rate (11%) of atrial fibrillation, which might have resulted from the smaller sample size in the present study and the multiple comorbidities. Nonetheless, this treatment-limiting side effect requires further elucidation. Paradoxical lymphocytosis at the outset of therapy was a common and benign finding. In conjunction with the reported trials, the IgG levels decreased in the first year of continued therapy. However, the IgA levels did not increase, even after 2 years of therapy. Micro-Abstract Ibrutinib, a novel Bruton tyrosine kinase inhibitor, has revolutionized the treatment of various B-cell malignancies. In this retrospective study, we analyzed the data of 45 patients with various B-cell malignancies to determine ibrutinib's clinical efficacy and adverse effects in a real-world setting. Results showed an excellent efficacy and a favorable toxicity but a higher incidence of atrial fibrillation.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research